Day: September 6, 2024

Fluent, Inc. to Participate in the 17th Annual Barrington Research Virtual Fall Investment Conference

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a partner monetization and customer acquisition solutions leader, today announced that Don Patrick, Chief Executive Officer, and Ryan Perfit, Interim Chief Financial Officer, will participate in the 17th Annual Barrington Research Virtual Fall Investment Conference on Thursday, September 12, 2024. Mr. Patrick and Mr. Perfit will be available for one-on-one meetings throughout the day. About Fluent, Inc.Fluent, Inc. (NASDAQ: FLNT) has been a leader in performance marketing since 2010, offering customer acquisition and partner monetization solutions that exceed client expectations. Leveraging untapped channels and diverse ad inventory across partner ecosystems and owned sites, Fluent connects brands with consumers at the most optimal moment, ensuring impactful...

Continue reading

Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

Written by Customer Service on . Posted in Public Companies.

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content JUPITER, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”), a wellness company behind the world’s first rapid alcohol reducer that lowers blood alcohol content (“BAC”) by supporting its metabolism in as little as 30 minutes, has announced the Notice of Allowance of for a U.S. patent that covers its newest clinically-backed formula. “This latest patent marks a significant milestone in Safety Shot’s quest to lead a brand-new category that the Company has created to solve alcohol related problems,” stated Safety Shot COO and co-owner of the patent, David Sandler. The Company’s family of patents aims to corroborate Safety Shot’s competitive advantage in the market which...

Continue reading

Titan Announces Filing of the Management Information Circular.

Written by Customer Service on . Posted in Public Companies.

TORONTO, Ontario, Sept. 06, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce the filing and mailing of its management information circular (the “Circular”) with respect to the amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”). This Transaction will constitute a reverse takeover of Titan. “The Circular sets out a compelling case for shareholders to approve Titan’s reverse merger with Conavi,” commented Paul Cataford, Titan’s Interim CEO and Board Chair. “After a thorough review of a number of potential transaction partners, Conavi came out on top. We believe the proposed Transaction offers our current Shareholders an opportunity to partially own an exciting...

Continue reading

EEW Renewables, a Global Renewable Energy Developer, and Compass Digital Acquisition Corp. Announce Definitive Business Combination Agreement

Written by Customer Service on . Posted in Mergers And Acquisitions.

EEW Renewables Ltd (“EEW” or the “Company”) is a global utility-scale renewable energy project developer across Europe and Australia with expertise across Solar PV, Battery Energy Storage System (“BESS”), and Green Hydrogen. Europe and Australia remain strong markets for renewable projects given the relatively low cost of installation, ease of grid connectivity, and attractive electricity rates. EEW has an established 12-year track record developing ~1.5 GW of renewable energy projects with compelling growth supported by a 9 GW project pipeline. EEW has a unique opportunity to evolve from a pure play developer into an independent power producer (“IPP”), attracting recurring revenue and attractive return on invested capital with the long-term goal of achieving IPP multiples in the public markets. The proposed transaction values EEW at...

Continue reading

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Written by Customer Service on . Posted in Mergers And Acquisitions.

Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc (“Clairvoyant”), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings of Clairvoyant (the “Proposed Acquisition”). As consideration for the Proposed Acquisition, Psyence Biomed will issue US$500,000 of the Company’s common...

Continue reading

Vivid Seats’ Game Center Debuts “Leagues” for NFL Season

Written by Customer Service on . Posted in Public Companies.

In-App Interactive, Free-To-Play Games Rewards Football Fandom with Free Tickets CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced new feature upgrades to Game Center, the brand’s innovative, in-app free-to-play product. Fans will now be able to win free National Football League (NFL) tickets each week and easily earn ticket credits in new ways this season, while competing against friends and family with Game Centers’ “Leagues” in the Vivid Seats app. In Vivid Seats’ Game Center, live event fans can play free daily games to score points towards ticket credits and enter drawings for free tickets. The addition of “Leagues”...

Continue reading

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Written by Customer Service on . Posted in Public Companies.

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an international patent application under the Patent Cooperation Treaty has been published for the innovative combination of 3,4-Methylenedioxymethamphetamine...

Continue reading

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Written by Customer Service on . Posted in Public Companies.

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines. The patent application was filed as part of the Company’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty pharmaceutical company in the clinical trial phase, dedicated...

Continue reading

Frequency Electronics, Inc. Announces Inaugural Quantum Sensing Summit: A Pioneering Event to Shape the Future of Quantum Technology

Written by Customer Service on . Posted in Public Companies.

MITCHEL FIELD, N.Y., Sept. 06, 2024 (GLOBE NEWSWIRE) — Today Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is proud to announce the inaugural Quantum Sensing Summit, an exclusive gathering of the brightest minds, leading industry players, and key government decision-makers dedicated to advancing the field of quantum sensing. As both host and sponsor, Frequency Electronics is committed to driving innovation and transforming research discoveries into real-world applications. The summit will be held on October 10-11, 2024 in New York, NY and will bring together leaders from government, research, and industry for a one-day event focused on “Achieving Production-Ready Quantum Sensing Technologies.” With an agenda designed to foster collaboration, the summit aims to bridge the gap between cutting-edge research and...

Continue reading

Casella Recognizes 2024 Sustainability Leaders

Written by Customer Service on . Posted in Public Companies.

Novolex, City of Biddeford, and Philips Academy honored for excellence in sustainability RUTLAND, Vt., Sept. 06, 2024 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST) (“Casella”), a regional solid waste, recycling, and resource management services company, recently honored three organizations for their leadership in sustainability as part of Casella’s annual Sustainability Leadership Awards. The Casella Sustainability Leadership Awards recognize partners and customers who best exemplify what we can achieve when we work together to reduce waste, increase recycling, and advance the circular economy. Each year, winners are selected from an inspiring slate of nominees, including municipalities, businesses, manufacturers, and higher education and healthcare institutions. “We are always excited to acknowledge and celebrate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.